Pharmaceuticals, Biotechnology & Life Sciences

Hemostemix Inc. battles financial turbulence while advancing blood‑derived cell therapies for severe disorders—investors watch its risky biotech comeback.

Celldex Therapeutics: Explore how the biotech company’s immunotherapy innovations target cancer, autoimmune, and infectious diseases, driving future breakthroughs.

Discover how EUROAPI SASU is shaping the global API market with innovative vitamin B12, prostaglandins, and anti‑infectives, and why investors keep a keen eye on its performance.

Explore Humacyte’s breakthrough in implantable bioengineered tissues, its market dynamics, and future growth prospects in the evolving biotech landscape.

Satellos Bioscience secures a 2044 U.S. patent for forazapadin, a Phase‑2 AAK1 inhibitor targeting Duchenne and facioscapulohumeral muscular dystrophy, boosting its muscle‑regeneration strategy.

Discover how AstraZeneca Pharma India’s new Massachusetts R&D hub in Kendall Square will boost drug discovery, especially for oncology, rare diseases, and metabolic disorders.

Explore Eton Pharmaceuticals’ journey—specialty injectables, oral liquids & ophthalmics—its rising stock, high valuation, and future growth potential.

Explore ABIONYX PHARMA SA’s volatile biotech journey—negative P/E, steep share swings, and the fight for profitability in an industry poised for breakthrough.

Explore how Conduit Pharmaceuticals revives overlooked clinical assets to accelerate new treatments, tackling unmet medical needs despite market volatility.

Genmab’s new Phase‑2 data on Rina‑S and Epcoritamab spark a sharp EU biotech rally, promising breakthrough front‑line cancer treatments and a surge in shareholder value.